Advertisement
Canada markets closed

  • S&P/TSX

    21,728.55
    +14.01 (+0.06%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • CAD/USD

    0.7282
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    79.27
    +0.27 (+0.34%)
     

  • Bitcoin CAD

    79,105.32
    -3,541.41 (-4.28%)
     

  • CMC Crypto 200

    1,267.95
    -71.12 (-5.31%)
     

  • GOLD FUTURES

    2,334.30
    +23.30 (+1.01%)
     

  • RUSSELL 2000

    1,980.23
    +6.32 (+0.32%)
     

  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     

  • NASDAQ futures

    17,543.50
    +105.25 (+0.60%)
     

  • VOLATILITY

    15.39
    -0.26 (-1.66%)
     

  • FTSE

    8,121.24
    -22.89 (-0.28%)
     

  • NIKKEI 225

    38,157.52
    -116.53 (-0.30%)
     

  • CAD/EUR

    0.6798
    +0.0005 (+0.07%)
     

Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Business Wire
·2 min read

CAMBRIDGE, England & BOSTON, April 02, 2024--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024, at 11 a.m. ET.

A live webcast of the fireside chat will be accessible from the Investor section of the company’s website at www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.

ADVERTISEMENT

Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240402089559/en/

Contacts

Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
ir@bicycletx.com
857-523-8544

Media:
Argot Partners
Deborah Elson
media@bicycletx.com
212-600-1902